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Abstract: Cardiac surgery with cardiopulmonary bypass (CPB) causes an acute lung ischemia-
reperfusion injury, which can develop to pulmonary dysfunction postoperatively. This sub-study
of the Pulmonary Protection Trial aimed to elucidate changes in arterial blood gas analyses,
inflammatory protein interleukin-6, and metabolites of 90 chronic obstructive pulmonary disease
patients following two lung protective regimens of pulmonary artery perfusion with either
hypothermic histidine-tryptophan-ketoglutarate (HTK) solution or normothermic oxygenated blood
during CPB, compared to the standard CPB with no pulmonary perfusion. Blood was collected
at six time points before, during, and up to 20 h post-CPB. Blood gas analysis, enzyme-linked
immunosorbent assay, and nuclear magnetic resonance spectroscopy were used, and multivariate
and univariate statistical analyses were performed. All patients had decreased gas exchange,
augmented inflammation, and metabolite alteration during and after CPB. While no difference
was observed between patients receiving oxygenated blood and standard CPB, patients receiving
HTK solution had an excess of metabolites involved in energy production and detoxification of
reactive oxygen species. Also, patients receiving HTK suffered a transient isotonic hyponatremia that
resolved within 20 h post-CPB. Additional studies are needed to further elucidate how to diminish
lung ischemia-reperfusion injury during CPB, and thereby, reduce the risk of developing severe
postoperative pulmonary dysfunction.
Keywords: COPD; ischemia-reperfusion; CPB; lung protection; pulmonary perfusion; HTK;
oxygenated blood; metabolites; randomized controlled trial
1. Introduction
In cardiac surgery, the use of cardiopulmonary bypass (CPB) deprives the pulmonary arteries of
blood flow, with the lung tissue reliant on blood supply from the bronchial arteries. Therefore, the lungs
are at risk of relative ischemia during CPB, followed by a reperfusion injury after weaning from CPB,
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which may cause impaired postoperative pulmonary function [1,2], particularly in patients with
preexisting lung disease. In this respect, patients with chronic obstructive pulmonary disease (COPD)
are more susceptible to CPB associated lung injury [3–5], as they are more vulnerable to the ceasing
of perfusion and ventilation [6–8]. The reduced pulmonary perfusion during CPB is accompanied
by a series of metabolic changes and bypass duration impacts not only the metabolic activity [9],
but also the fibrinolytic cascade [10]. Eventually, these events lead to pulmonary dysfunction with
subsequent hypoxemia, and in the most severe cases to development of acute respiratory distress
syndrome [11–13]. Studies of acute respiratory failure have identified a characteristic hallmark of
lung injury with overall energy depletion [14], activated lipid metabolism, augmented anaerobic
environment, proteolysis, oxidative stress [15], apoptosis [16], and endothelial disruption [17].
Previous studies suggest that pulmonary artery perfusion during CPB may diminish
ischemia-reperfusion injury, and subsequent pulmonary dysfunction, by supplying metabolic
substrates to the lungs [18–21] and by reducing cellular oxygen consumption [22–28]. A wide variety
of protective solutions are routinely used, however, there is an ongoing discussion about the relative
effectiveness of these solutions with regards to tissue protection during an ischemia-reperfusion
period [29]. Warm or cold autologous blood [22–28] and crystalloids [18–21] are the main preservative
solutions used in cardiac surgery. The crystalloid solutions can be classified into those based on
extracellular components with high potassium, magnesium, and bicarbonate levels; and those based
on intracellular electrolytes. The hypothermic histidine-tryptophan-ketoglutarate (HTK) solution is
an extracellular based preservation solution used for organ (e.g., lung) transplantation [21,30–32],
in addition to its use as a cardioplegic agent. Preservation with HTK-Custodiol (Koehler Chemi,
GMBH, Germany), or its equivalent Bretschneider solution [33–35], is administered as a single dose
and claimed to give organ protection for more than two hours [36]. The solution contains 15 mM Na+,
9 mM K+, 4 mM Mg++, 0.015 mM Ca++, 198 mM histidine, 2 mM tryptophan, 1 mM 2-ketoglutarate,
and 30mM mannitol, with a pH of 7.02–7.2 at 25 ◦C (77 ◦F) [37]. The included histidine is thought
to have a buffer effect associated with enhanced efficiency of anaerobic glycolysis; tryptophan and
mannitol are proposed to function as cell membrane stabilizers and as reducing agents to prevent
the formation of cellular edema; whereas 2-ketoglutarate is an intermediate of the tricarboxylic acid
(TCA) cycle and a precursor of nicotinamide adenine dinucleotide which is assumed to serve in
energy production [36]. Several studies have demonstrated the efficacy of HTK solution in preserving
myocardial adenosine triphosphate stores, improving post-arrest contractile function and minimizing
myocardial necrosis [38,39]. Careaga and colleagues [40] reported that patients receiving cardioplegia
with HTK solution had a decreased incidence of postoperative arrhythmias, length-of-stay in the
intensive care unit, and inotropic support; while Lin and colleagues [41] have shown that blood
transfusions, mortality, morbidity, and hospital readmission were significantly lower compared to those
receiving another extracellular based cardiologic solution (St. Thomas’ Hospital solution, 144 mEq Na+,
20 mEq K+, 32 mEq Mg++, and 4.8 mEq Ca++ per liter solution, pH 5.5).
In an experimental rat model of ex vivo lung perfusion, it was found that HTK solution attenuated
pulmonary edema until 12 h post-perfusion compared to both saline and low-potassium dextran
solution, another extracellular based preservation solution [42,43]. We have recently shown that
lung ischemia-reperfusion injury during CPB is characterized by augmented inflammation, metabolic
acidosis, protease activity, and oxidative stress and that patients receiving lung protection with
HTK solution seemed better protected against severe acidosis, excessive fatty acid oxidation, and
inflammation compared to pulmonary artery perfusion with normothermic oxygenated blood or no
pulmonary perfusion during CPB [44]. Besides HTK, pulmonary artery perfusion with normothermic
oxygenated blood during CPB has also been found to reduce lung ischemia-reperfusion injury with
improved postoperative oxygenation and lung compliance, and reduced intubation time [22,26,27,45].
In the original paper, from the randomized Pulmonary Protection Trial of adult patients undergoing
elective cardiac surgery [46], we found that postoperative arterial oxygenation was higher 20 h
post-CPB in patients receiving pulmonary perfusion with oxygenated blood during CPB, compared to
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those receiving HTK solution or standard CPB without pulmonary perfusion. However, baseline mean
arterial oxygenation was 20% higher in the patients receiving pulmonary perfusion with oxygenated
blood compared to the two other groups baseline values [46].
Currently, no randomized studies have compared the effects of pulmonary artery perfusion with
HTK solution or oxygenated blood, versus standard CPB, and little is known about the molecular
mechanisms of these regimens. Hence, the main aim of this sub-study is to compare the molecular
effects of hypothermic HTK solution and normothermic oxygenated blood to the standard CPB regimen
without pulmonary perfusion, on blood obtained from COPD patients included in the randomized
Pulmonary Protection Trial [46]. In particularly, we aim to find changes in arterial blood gases,
electrolytes, plasma inflammatory protein interleukin-6 (IL-6), and plasma metabolites associated with
ischemia-reperfusion injury and the received regime. Blood samples were collected from 90 patients
undergoing cardiac surgery at baseline (pre-CPB), immediately after weaning from CPB (end CPB), and
the following 2, 4, 6, and 20 h after weaning from CPB. Profound blood gas, electrolyte, inflammatory
protein, and metabolite changes were detected during and after CPB in all patients, regardless of the
treatment received. While all patients had decreased gas exchange, augmented inflammation, and
metabolite alterations, patients receiving HTK solution had an excess of metabolites involved in energy
production and detoxification of reactive oxygen species. In addition, patients receiving HTK suffered
a transient isotonic hyponatremia that resolved within 20 h post-CPB.
2. Materials and Methods
The Pulmonary Protection Trial (ClinicalTriAls.gov Identifier: NCT01614951) was conducted
in accordance with the Declaration of Helsinki and approved by the Biomedical Research Ethics
Committees of The Capital Region of Denmark (H-1-2012-024), the Danish Medicines Agency
(2012024017; EudraCT, 2011-006290-25, 4141), and the Danish Data Protection Agency (2011-41-7051).
The rationale for, design, and primary results of the trial have been previously published [44,46,47].
2.1. Patient Population, Interventions, and Sample Collection
After obtaining informed consent, 90 patients scheduled for elective coronary artery bypass
grafting, aortic valve replacement, or both of the aforementioned procedures were included. Inclusion
criteria were adults (≥18 years) with COPD. Exclusion criteria were patients with previous heart or lung
surgery, previous thoracic radiation, left ventricular ejection fraction <20%, tracheal intubation, and/or
medically treated pneumonia prior to surgery. Patients underwent an overnight fast, standardized
anesthesia and surgical management, and were assigned to receive the standard CPB regimen or
pulmonary artery perfusion, with either continuous normothermic oxygenated blood during CPB or a
single-shot hypothermic of HTK solution at the same time as the first cardioplegia (Figure 1).
Immediately after anesthetic induction, a catheter was inserted in the pulmonary artery and
blood samples for interleukin-6 (IL-6) and metabolite analysis were drawn at baseline (pre-CPB),
immediately after weaning from CPB (end CPB), and the following 2, 4, 6, and 20 h after weaning from
CPB. Samples were simultaneously drawn from a catheter in arteria radialis for immediate blood gas
analysis. The 768 blood samples from the pulmonary artery were immediately centrifuged at 4 ◦C to
obtain plasma. Aliquots were stored at −80 ◦C until analysis.
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Figure 1. Description of the three interventions: (a) standard cardiopulmonary bypass (CPB) without 
perfusion of the pulmonary circuit; (b) CPB plus continuous pulmonary artery perfusion with 
normothermic oxygenated blood (400 mL/min); (c) CPB plus pulmonary artery perfusion with a 
single-shot of histidine-tryptophan-ketoglutarate (HTK) solution (2000 mL). The volume returning to 
the left atrium from the pulmonary circuit was filtered by a cell saver, only returning the red blood 
cells to the heart and lung machine’s venous reservoir. At the end of CPB, reperfusion of the 
pulmonary circuit added approximately 500 mL HTK solution to the systemic circuit. 
2.2. Interleukin-6 
Plasma IL-6 levels were determined using a commercial enzyme-linked immunosorbent assay 
(ELISA) kit (Human IL-6 ELISA Ready-SET-Go; eBioscience, San Diego, CA, USA) according to the 
manufacturer’s protocol. Samples were run in duplicate, and the mean was obtained. 
2.3. Nuclear Magnetic Resonance (NMR) Spctroscopy 
Plasma samples were thawed for 30 min at 4 °C and centrifuged for 5 min (4 °C, 12,100x g) to 
remove cells and precipitate. Aliquots of 400 μL of supernatant were mixed with 200 μL D2O 
phosphate buffer (0.2 M Na2HPO4/NaH2PO4, pH 7.4, in 99% 2H2O; Sigma-Aldrich, Germany) and 
subsequently recorded on a BRUKER AVIII-600 MHz NMR spectrometer (BrukerBioSpin, Germany) 
equipped with a CPP-TCI probe (Bruker BioSpin, Switzerland) at a temperature of 298.1 K. 1H NMR 
spectra were acquired using a T2-filtered one-dimensional Carr–Purcell–Meiboom–Gill (CPMG) [48] 
pulse sequence with water suppression, as previously described [9,15]. Spectral acquisition was 
controlled using the TopSpin 3.1 software (Bruker BioSpin, Germany). 
2.4. Data Analysis 
Spectra were manually phased and baseline corrected, calibrated to the methyl peaks of L-
alanine at 1.48 ppm, and regions containing water and ethylenediaminetetraacetate EDTA signals 
Figure 1. Description of the three interventions: (a) standard cardiopulmonary bypass (CPB) without
perfusion of the pulmonary circuit; (b) CPB plus continuous pulmonary artery perfusion with
normothermic oxygenated blood (400 mL/min); (c) CPB plus pulmonary artery perfusion with a
single-shot of histidine-tryptophan-ketoglut rate (HTK) solution (2000 mL). The volume retur ing to
the left atrium from the pul o ar i i filtered by a cell saver, only returni g the r d blood cells
to the heart and lu g machine’s venous reservoir. At the end of CPB, reperfusion of the pulmonary
circuit added approxim tely 500 mL HTK solution to the systemic circuit.
2.2. Interleukin-6
Plasma IL-6 levels were determined using a commercial enzyme-linked immunosorbent assay
(ELISA) kit (Human IL-6 ELISA Ready-SET-Go; eBioscience, San Diego, CA, USA) according to the
manufacturer’s protocol. Samples were run in duplicate, and the mean was obtained.
2.3. Nuclear Magnetic Resonance (NMR) Spctroscopy
Plasma samples were thawed for 30 min at 4 ◦C and centrifuged for 5 min (4 ◦C, 12,100× g)
to remove cells and precipitate. Aliquots of 400 µL of supernatant were mixed with 200 µL D2O
phosphate buffer (0.2 M Na2HPO4/NaH2PO4, pH 7.4, in 99% 2H2O; Sigma-Aldrich, Germany) and
subsequently recorded on a BRUKER AVIII-600 MHz NMR spectrometer (BrukerBioSpin, Germany)
equipped with a CPP-TCI probe (Bruker BioSpin, Switzerland) at a temperature of 298.1 K. 1H NMR
spectra were acquired using a T2-filtered one-dimensional Carr–Purcell–Meiboom–Gill (CPMG) [48]
pulse sequence with water suppression, as previously described [9,15]. Spectral acquisition was
controlled using the TopSpin 3.1 software (Bruker BioSpin, Germany).
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2.4. Data Analysis
Spectra were manually phased and baseline corrected, calibrated to the methyl peaks of L-alanine
at 1.48 ppm, and regions containing water and ethylenediaminetetraacetate EDTA signals were
removed. Data was reduced to equal buckets of 0.001 ppm bin widths, generalized log transformed,
normalized, and mean centered. Analysis was performed in the matrix laboratory MATLAB (R2011b,
MathWorks, Natick, MA, USA) and IBM®SPSS Statistics (v.22, SPSS Inc., Armonk, NY, USA).
For multivariate analysis unsupervised principal component analysis was applied using the Partial
Least-Square PLS-Toolbox 6.5 (Eigenvector Research, Wenatchee, WA, USA). Signals contributing to
sample clustering were identified and quantified as previously described [9,15]. Concentrations
are presented as mean ± standard deviation and percent change, calculated by the formula
(postCPB−preCPB)/preCPB·100.
The interactions between time- and treatment-dependent changes were determined by two-way
analysis of variance (ANOVA) with Tukey’s post-hoc test for multiple comparisons. Statistical
significance was defined as a p-value ≤0.05.
3. Results
3.1. Patient Characteristics
A total of 90 patients were randomized to receive either the standard CPB regimen with
no pulmonary perfusion, continues pulmonary artery perfusion with normothermic oxygenated
blood, or single-shot pulmonary perfusion with HTK solution. There was one post-randomization
exclusion where cross-clamping to initiate CPB was not possible due to a fragile aorta. For this
sub-study, the per-protocol population consisted of 34 patients receiving standard CPB, 28 receiving
pulmonary perfusion with oxygenated blood, and 27 receiving pulmonary perfusion with HTK
solution. Patient characteristics, medical history, preoperative pulmonary function, and surgical data
are presented in Table 1. Eighty-seven patients were Caucasians, one Inuit, and one of Arabic origin.
There were no statistically significant differences between the groups.
Table 1. Clinical and procedural characteristics (per-protocol population).
Standard CPB
(n = 34)
O2 Blood
(n = 28)
HTK Solution
(n = 27)
Patient characteristics
Age—year (mean ± SD) 70.2 ± 8.5 69.6 ± 10.7 69.8 ± 8.3
Male sex—number (%) 28 (82.4) 21 (75.0) 18 (66.7)
BMI (mean ± SD) 22.9 ± 4.2 23.1 ± 5.2 22.8 ± 4.0
Medical history—number/total number (%)
Self-reported COPD 21/34 (61.8) 14/28 (50.0) 17/27 (63.0)
Pulmonary hypertension † 7/26 (27.0) 3/23 (13.0) 6/24 (25.0)
Arterial hypertension 24/34 (70.6) 22/28 (78.6) 23/27 (85.2)
Chronic atrial fibrillation or flutter 5/34 (14.7) 4/28 (14.3) 3/26 (11.5)
Chronic heart failure ‡ 10/32 (31.3) 12/28 (42.9) 6/27 (22.2)
ASA class IV or worse 6/32 (18.8) 1/28 (3.6) 2/25 (8.0)
Left ventricular ejection fraction (IQR) 50.0 (45.0–60.0) 55.0 (45.0–60.0) 50.0 (40.0–60.0)
Recent AMI § 10/34 (29.4) 6/28 (21.4) 9/27 (33.3)
Diabetes mellitus 9/34 (26.5) 8/28 (28.6) 3/27 (11.1)
Estimated creatinine clearance (IQR) ** 86.6 (70.0–106.0) 81.4 (61.8–122.9) 82.7 (62.7–112.8)
Previous transient ischemic attack or stroke 7/34 (20.6) 1/28 (3.6) 7/27 (26.0)
Previous percutaneous coronary intervention 6/34 (17.7) 4/28 (14.3) 5/27 (18.6)
Implantable cardioverter defibrillator or pacemaker 1/32 (3.1) 2/27 (7.4) 1/26 (3.9)
Excess alcohol consumption †† 7/34 (20.6) 11/28 (39.3) 7/27 (26.0)
Tobacco pack years (IQR) 35.0 (22.5–47.5) 35.0 (17.8–50.0) 40.0 (30.0–50.0)
Pulmonary function on admission
Percent predicted FEV1 (IQR) 73.5 (56.8–89.0) 78.0 (58.3–87.8) 79.0 (60.0–87.0)
GOLD I (Mild) 13/34 (38.2) 14/28 (50.0) 13/27 (48.2)
GOLD II (Moderate) 18/34 (53.0) 11/28 (39.3) 13/27 (48.2)
GOLD III (Severe) 2/34 (5.9) 3/28 (10.7) 1/27 (3.7)
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Table 1. Cont.
Standard CPB
(n = 34)
O2 Blood
(n = 28)
HTK Solution
(n = 27)
GOLD IV (Very severe) 1/34 (2.9) 0/28 (0.0)
Surgical data
AVR 12/34 (35.3) 7/28 (25.0) 7/27 (26.0)
CABG 20/34 (58.8) 14/28 (50.0) 15/27 (55.6)
CABG + AVR 2/34 (5.9) 7/28 (25.0) 5/27 (18.5)
Surgical time, min. 197.4 ± 67.2 197.6 ± 75.8 200.3 ± 36.3
Cardiopulmonary bypass time, min. 98.1 ± 42.7 102.7 ± 54.7 101.2 ± 27.4
Aortic cross-clamp time, min. 61.7 ± 33.4 59.5 ± 38.3 63.8 ± 18.9
Gain volume, L 1.2 ± 0.9 1.6 ± 0.9 1.2 ± 1.0
Abbreviations: CPB, cardiopulmonary bypass; SD, standard deviation; AMI, acute myocardial infarction; ASA,
American Society of Anesthesiologists; AVR, aortic valve replacement; CABG, coronary artery bypass graft; COPD,
chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; GOLD, global initiative
for chronic obstructive lung disease; HTK, histidine-tryptophan-ketoglutarate; ICU, intensive care unit; IQR,
interquartile range. † Determined by preoperative echocardiography. ‡ Chronic heart failure, New York heart
association Class III or worse. § Recent AMI <3 months prior to the surgery. Insulin and non-insulin dependent
diabetes mellitus. ** Estimated creatinine clearance by Cockcroft–Gault equation in mL/min/1.73 m2. †† Excess
alcohol consumption, >14 for women and >21 for men units’ alcohol per week.
3.2. Clincal Outcomes, Arterial Blood Gas Analyses, and Inflammatory Protein
All clinical outcomes have previously been published [46] and later included in a systematic
review [49]. No significant differences were found between the three groups with respect to
postoperative oxygenation, intubation time, days alive outside the intensive care or hospital, 90-day
mortality, and serious adverse events.
Arterial blood gas analyses are presented in Table 2. At the end of CPB, pH levels dropped
slightly in all patients, with more pronounced decreases in the HTK-receiving patients, due to a
relatively lower pH of the received solution (7.02–7.20). Base excess and bicarbonate also decreased
with unchanged partial pressure of carbon dioxide in accordance with the HTK driven metabolic
acidosis although without changes in lactate. At 20 h post-CPB, pH levels returned to pre-surgical
values in all patients. The partial pressure of carbon dioxide was in all patients within normal range
during the whole observation period. The partial pressure of oxygen was, in all patients, above
physiological values from pre-CPB until normalization 20 h post-CPB. Likewise, arterial blood glucose
and lactate levels increased right after CPB in all patients regardless of the treatment received, and
remained elevated through the following 20 h post-CPB. Lastly, sodium and potassium also changed
post-CPB; while potassium increased, sodium decreased immediately after CPB, especially in the
HTK-receiving patients, and nearly returned to their baseline levels 20 h after CPB.
The systemic inflammatory response, generated by contact activation of cells passing through
the extracorporeal CPB circuit in addition to the ischemia-reperfusion injury, was assessed by the
pro-inflammatory mediator IL-6 (Table 2). A steep increase was observed in all patients immediately
after weaning from CPB and its concentration remained elevated through all post-CPB measurements.
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Table 2. Results of arterial blood gas analyses and interleukin-6 in samples collected before CPB, at the end of CPB, and 2, 4, 6, and 20 h post-CPB.
Pre-CPB End CPB 2 Hours Post-CPB 4 Hours Post-CPB 6 Hours Post-CPB 20 Hours Post-CPB Time
(p-value)
Time
-Group
(p-value)Standard HTK O2 Standard HTK O2 Standard HTK O2 Standard HTK O2 Standard HTK O2 Standard HTK O2
pH
Mean 7.39 7.40 7.40 7.39 7.34 7.37 7.32 7.29 7.32 7.31 7.28 7.32 7.32 7.29 7.32 7.37 7.38 7.37
0.15 0.38
SD 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.06 0.08 0.06 0.05 0.08 0.05 0.04 0.08 0.05 0.04 0.06
pCO2
(kPa)
Mean 5.6 5.6 5.4 4.8 5.1 5.0 5.9 5.9 5.7 6.0 6.0 5.6 5.8 5.7 5.6 5.4 5.2 5.2
3.81 × 1016 0.87
SD 0.6 0.8 0.6 0.5 0.7 0.5 0.7 1.0 1.2 0.7 0.7 1.1 0.6 0.7 0.9 0.8 0.6 0.5
pO2 (kPa)
Mean 44.8 35.5 40.6 34.4 22.5 31.7 18.0 19.9 19.7 14.9 15.0 18.7 14.2 13.7 15.8 12.4 11.5 13.5
7.82 × 1089 0.04
SD 12.6 9.2 14.5 14.4 11.6 14.2 6.5 7.3 6.9 3.8 4.3 8.6 3.3 3.0 3.2 2.6 2.0 2.8
sO2 (%)
Mean 99.7 99.8 99.6 99.6 98.4 99.0 98.2 98.3 98.2 96.7 97.6 98.3 96.7 97.1 97.9 97.3 96.9 97.9
0.01 0.27
SD 0.7 0.3 1.1 1.0 2.1 1.9 2.0 1.6 2.3 6.8 1.6 2.7 5.8 2.3 2.6 2.1 1.7 1.8
Hb
(mmol/L)
Mean 7.6 7.6 7.3 5.8 5.9 5.6 6.9 7.2 6.6 7.0 7.2 6.6 7.0 7.1 6.5 6.6 6.6 5.6
6.49 × 1031 0.04
SD 0.9 0.9 0.9 0.8 0.8 0.6 0.9 0.9 0.6 1.0 0.9 0.7 0.9 1.0 1.0 1.0 0.8 1.3
Hct (%)
Mean 37.6 37.6 36.2 28.9 29.3 28.1 34.4 35.7 33.0 34.8 35.9 32.7 34.8 35.0 32.3 33.0 33.0 29.0
9.45 × 1030 0.17
SD 4.6 4.6 4.4 3.8 3.8 3.0 4.1 4.2 3.0 4.7 4.1 3.5 4.5 5.0 4.7 4.7 4.1 4.0
K+
(mmol/L)
Mean 3.9 3.8 3.8 5.1 5.3 4.8 5.1 5.1 4.7 4.8 4.7 4.5 4.7 4.6 4.4 4.4 4.2 4.4
7.89 × 1039 0.006
SD 0.2 0.3 0.4 0.6 0.5 0.4 0.5 0.6 0.5 0.5 0.5 0.6 0.7 0.6 0.5 0.4 0.4 0.3
Na+
(mmol/L)
Mean 137.5 138.1 137.8 134.8 129.9 135.2 135.9 133.0 136.8 136.7 135.2 137.7 137.4 136.5 138.8 137.5 137.4 138.8
0.002 0.01
SD 2.6 2.2 3.2 2.4 3.0 2.0 2.8 2.4 2.4 3.0 3.1 2.8 2.7 3.2 2.6 2.9 2.0 4.0
Ca++
(mmol/L)
Mean 1.18 1.17 1.17 1.22 1.24 1.25 1.23 1.21 1.23 1.18 1.19 1.19 1.17 1.17 1.17 1.13 1.13 1.13
5.97 × 1010 0.98
SD 0.06 0.04 0.04 0.18 0.11 0.12 0.09 0.08 0.08 0.07 0.07 0.07 0.06 0.05 0.06 0.05 0.05 0.05
HCO3−
(mEq/L)
Mean 24.5 25.1 24.7 22.1 20.3 21.8 21.8 19.9 21.1 21.2 19.8 20.9 21.4 19.8 20.8 22.8 22.9 22.8
1.93 × 1032 1.96 × 108
SD 1.6 1.6 1.7 1.8 1.4 1.6 1.9 1.5 1.7 2.4 1.4 1.9 2.0 1.7 2.2 2.0 2.0 2.2
SBE
Mean 0.2 0.8 0.3 −3.1 −5.0 −3.2 −2.9 −5.1 −3.8 −3.5 −5.1 −4.0 −3.3 −5.4 −4.2 −1.8 −1.9 −2.0
3.14 × 1044 0.0003
SD 1.9 1.8 2.0 2.2 1.7 1.9 2.3 1.9 1.8 3.0 1.8 2.1 2.4 2.2 2.7 2.5 2.5 2.7
Glucose
(mmol/L)
Mean 6.4 6.3 6.4 6.9 7.4 7.5 7.3 8.3 8.2 8.6 9.2 9.2 9.0 9.2 8.7 7.7 8.0 8.0
3.36 × 1023 0.84
SD 1.6 1.4 1.5 1.8 1.5 1.6 1.7 2.6 1.6 2.0 2.5 2.0 1.6 1.5 1.5 2.1 1.4 1.6
Lactate
(mmol/L)
Mean 0.7 0.7 0.8 1.6 1.8 1.9 1.2 1.4 1.4 1.5 1.9 1.9 1.7 2.0 2.2 1.3 1.3 2.0
1.49 × 109 0.70
SD 0.3 0.2 0.3 0.5 0.5 0.6 0.6 0.6 0.6 1.0 1.6 1.2 1.1 1.2 1.6 1.1 0.6 3.3
IL-6
(pg/mL)
Mean 4.9 2.9 13.1 26.2 23.3 55.2 61.0 63.0 98.3 61.0 59.8 96.1 71.5 61.8 96.1 67.8 53.1 100.4
3.74 × 107 0.45
SD 11.6 2.3 52.4 21.9 17.0 85.0 49.4 56.9 153.2 62.5 58.8 159.7 91.7 98.5 189.4 93.1 50.2 192.0
Two-way ANOVA (analysis of variance) and its corresponding Tukey’s post-hoc test for group comparison was used to detect differences between patients as a consequence of surgery
(time) and treatment received (time-group interaction). A two-tailed p-value≤0.05 was considered significant. Ca++, calcium; IL-6, interleukin-6; K+, potassium; Na+, sodium; pCO2, partial
pressure of carbon dioxide; pH, acidity/alkalinity; pO2, partial pressure of oxygen; HCO3−, bicarbonate; SBE, base excess; sO2, saturation of oxygen; Hb, haemoglobin; Hct, haematocrit.
J. Clin. Med. 2018, 7, 462 8 of 18
3.3. Plasma Metabolites
Figure 2 illustrates the aliphatic region of one-dimensional 1H-NMR spectra of median plasma
samples collected before CPB (blue), at the end of CPB (cyan), 2 h post-CPB (green), 4 h post-CPB
(brown), 6 h post-CPB (orange), and 20 h post-CPB (yellow). Visual inspection of spectra reveals
that the intensity of several metabolites changed significantly in the peri- and postoperative period,
reflecting alterations in their levels as a consequence of surgery.
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Principal component analysis revealed sample clustering according to sample time (principal
component one, PC1 = 36.9%, Figure 3A) nd treatment received uring CPB (PC2 = 17.6%, F gure 3B).
As observed in Figure 3A, samples collect d before (blue) and at the end of CPB (cyan) clustered
separately from each other, indicating that the ischemia-reperfusio injury itself had a significant
impact n the metabolome. Lo er duration of CPB resulted i greater increases of anaerobic (i.e.,
lactate; Pearson correlation coefficien r = 0.4, p < 0.0001) and TCA cycle (i.e., citrate; r = 0.4, p < 0.0001)
metabolites, and greater dilution of plasma fatty acids and ipoproteins ( −0.32, p < 0.0001)
(Figure 3C). Samples collected 2–6 h post-CPB tended to retu n towards baseline, and at 20 h post-CPB
s almost reached their corresponding pre-CPB values (Figure 3A). When col ring principal
co onent analysis scores by the intervent on received, HTK patients clustered s parately on the
PC2 axis at the end of CPB, while pat ents receiving normothermic oxygenated blood over apped
with patients receiving standard CPB, ndic ting imilar metab lite c anges in the oxygenated blood
nd standard CPB groups. A total of 41 identified me abolites were found to contribute to sample
clustering along PC1 PC2 (Supplementary, Table S1. Ov rv ew of metabolite changes with ime in
each corresponding group), of which several were found to be influenced by both th surgery itself
and the received treatment (Figure 3D).
An overview of all metabolites is provi ed in Figure 3E and their pathways in Figure 4.
Several metabolites involved in glycolysis, amino acid metabolism, ketone synth sis, ur a cycle,
TCA cycle, protein and fatty acid metabolism, and glucose-derivate met bolism were found to
be affected fter CPB. Among these, glycolytic metabolites (e.g., glucose, myo-inositol, fucose,
mann se, p o phoenoy pyruvate, pyruvate, and lactat ), urea cycle metabolites (e.g., arginine,
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citrulline, proline, and urea), several amino acids (e.g., lysine, valine, leucine, tyrosine, phenylalanine,
and creatinine), and ketone bodies (e.g., acetoacetate, acetone, and 3-hydroxybutyric acid) were all
increased immediately after CPB in all patients, irrespective of the received intervention (Figure 4).
The protein derived N-acetyl-glycoprotein fragments, lipoproteins, and fatty acids (e.g., free fatty acids,
monounsaturated fatty acids, and triacylglycerol) were decreased in all patients at the end of CPB, due
to hemodilution by the CPB-pump priming solution, with the lowest values for the HTK-receiving
patients, who received an additional volume with of HTK solution. HTK-receiving patients had
higher mannitol levels at the end of CPB compared to the standard and oxygenated blood receiving
patients, due to the additional mannitol from the HTK solution. Increased levels of the drug clearance
metabolite glucuronic acid and its precursor, myo-inositol, were observed in all patients from 2 to
20 h post-CPB, with marginally higher levels in the HTK group. After administration of HTK, plasma
histidine levels increased markedly, from a physiological value of 0.068 mM to 6.4 mM at the end
of CPB and were still 7-times above physiological values 20 h post-CPB (0.47 mM). In comparison,
histidine levels in the standard regimen and oxygenated blood groups did not change more than 10%
during the same period. Within the same interval, plasma glutamate, glutamine, aspartate, threonine,
methionine, creatine, glycine, alanine, format, and 2-ketoglutarate were all elevated in the HTK group
compared to the standard and oxygenated blood groups. Lastly, citrate levels increased to a minor
degree postoperatively in the HTK-receiving patients compared to the patients receiving oxygenated
blood or standard CPB.
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Figure 3. etabolo e changes as a consequence of the surgical procedure and lung protection regimen
received. (A) Principal component analysis (PCA) scores plot containing NMR spectral data of plasma
collected before CPB (blue), at the end of CPB (cyan), 2 h (green), 4 h (brown), 6 h (orange), and 20 h
post-CPB (yellow). Samples cluster according to the ti e of sample collection. (B) Same PCA scores plot
as in (A) but samples are color coded according to intervention group: standard CPB with no pulmonary
perfusion (black), pulmonary artery perfusion with hypothermic histidine-tryptophan-ketoglutarate
(HTK) (blue), pulmonary artery perfusion with normothermic oxygenated blood (O2 blood) (red).
CL, confidence level; PC, principal component 1 and 2. (C) Correlation of metabolites concentrations
measured at the end of CPB with CPB duration; lactate, pyruvate, and citrate levels increased (+), while
monounsaturated fatty acids (MUFA) and lipoprotein levels decreased (−, with a longer duration
of CPB. (D) Pie plot representation of metabolites demonstrated significant changes over time as a
consequence of CPB (purple) and treatment allocation (white) explored by means of two-way ANOVA.
(E) Heat map representation of mean percent changes of metabolites in relation to pre-operative values.
Mean percent changes were calculated using the formula (postCPB − preCPB)/preCPB·100. Green:
lower concentration; red: higher concentration. 3-HBA, 3-hydroxybutyric acid; NAc-Glc, N-acetylated
glycoprotein fragment; TAG, triacylglycerol; FA, fatty acid; MUFA, monounsaturated fatty acid.
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4. Discussion
To the best of our knowledge, this is the first study to investigate the metabolic response in
COPD patients undergoing cardiac surgery randomized to receive either pulmonary artery perfusion
with oxygenated blood or HTK solution, compared to standard CPB regimen without pulmonary
perfusion. The main aim of this sub-study was to investigate the molecular effects of the two pulmonary
perfusion regimes compared to standard CPB, on blood obtained from COPD patients included
in the randomized Pulmonary Protection Trial [46]. In particularly we aimed to find changes in
arterial blood gas, electrolytes, plasma inflammatory protein IL-6, and plasma metabolites associated
with hypothesized ischemia-reperfusion injury and the received regimen. The results should be
interpreted with respect to some important limitations. Although cardiac surgical patients are
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relative homogenous, outcomes are, besides the interventions, influenced by the individual patient’s
comorbidities, which may leave the study underpowered to detect any group differences. In addition,
our follow-up period was limited to 20-h post CPB, which is not the time of maximal pulmonary
damage, which questions the generalizability of our results.
4.1. Clincal Outcomes, Arterial Blood Gas Analyses, and Inflammatory Protein
As previously published, we found no significant differences in any of the clinical outcomes
between the three groups [46,49]. Overall, arterial blood gas analyses were affected by surgery in all
three groups. We found that sodium changed more significantly in the HTK receiving patients
at the end of CPB. This is in line with previous findings by Lindner et al. [50] describing the
development of isotonic hyponatremia following cardioplegia with HTK solution. They concluded
that hyponatremia should not be corrected without concomitant hypotonicity, as it may, in fact, cause a
significant increase in serum osmolarity, which can be associated with neurological complications [41].
Hyponatremia in the presence of unchanged osmolarity was also found by Viana and colleagues [37],
following cardioplegia with HTK solution, which supports our findings and the strategy of not
correcting the transitory electrolyte changes following administration of HTK solution.
Cardiac surgery with CPB is known to trigger a significant postoperative systemic inflammatory
response, which may result in multiple-organ dysfunction associated with a poor clinical outcome [51].
The proinflammatory mediator IL-6 has previously been found to be increased after CPB, reaching
peak levels 4–6 h after weaning from CPB and to decrease to normal levels within 24–48 h [52–54].
Our results confirm this increase in IL-6 levels following CPB, with peak levels reached at 2–6 h
post-CPB. Although the HTK receiving patients in general had lower plasma IL-6 levels compared
to the oxygenated blood and standard CPB regimen groups, there was no statistically significant
difference between groups. These results are in line with our previous finding in bronchoalveolar
fluid [44], where we found an increased production of inflammatory cells in the lungs of these patients,
irrespective of the treatment received. Interestingly, at our last measurement 20 h post-CPB IL-6 levels
had not declined as expected [52], presenting levels as high as those measured two hours post-CPB.
Patients with COPD have previously been reported to exhibit a dysfunctional immune response
compared with healthy control subjects [55,56]. How the immune response following the insult of
cardiac surgery and CPB differs in patients with COPD is largely unknown, but our results suggest an
altered time course with a slower resolution of inflammation.
4.2. Plasma Metabolites
Several metabolites changed significantly in the peri- and postoperative periods, with the largest
differences between the pre- and post-CPB samples. The patients’ metabolomes tended to return
towards preoperative state at the last measurement (20 h post-CPB); however, several metabolite levels
were still altered at this time point. Collecting samples from later points could have demonstrated
the exact time when the metabolome regained its normal preoperative level. Several metabolites
correlated with the duration of CPB, indicating that a prolonged surgical procedure influenced the
metabolite levels, with increased anaerobic metabolism and decreased levels of fatty acids, lipids, and
glycoproteins. This is in line with previously published results where we also found a correlation
between the same metabolites and the duration of CPB in patients undergoing elective coronary artery
bypass grafting [9].
Major surgery leads to a general surgical stress response nearly doubling patients’ energy
requirements. Easily accessible carbohydrates and fats are used first; while muscle catabolism
yielding branched chain amino acids are used later on to serve as carbon chains for the unmet
energy needs, with valine being converted to carbohydrates, leucine to fats, and isoleucine to fats as
well as carbohydrates [57–60]. In our study the levels of free fatty acids, lipoproteins, monounsaturated
fatty acids, triacylglycerol, and N-acetyl-glycoprotein fragments were significantly lower at the end
of CPB. Their levels increased in the hours following surgery, but without reaching baseline levels.
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The drop in the N-acetyl-glycoprotein and lipoprotein macromolecules was more pronounced in the
HTK receiving patients, compared to those receiving pulmonary perfusion with oxygenated blood or
standard CPB. This can be explained by the possible entrapment of some of the macromolecules in
the cell saver used to collect the administered HTK solution. Analyzing samples from the cell saver
would confirm or reject this statement. The levels of carbohydrates and branched chain amino acids
increased in all patients at the end of CPB and their levels almost normalized within 6–20 h post-CPB,
with some exceptions.
Overall, we found no significant metabolite differences in patients receiving pulmonary artery
perfusion with oxygenated blood compared to those receiving the standard regimen. Not even
lactate, which, theoretically, should be reduced in patients receiving additional perfusion of the
pulmonary circulation with oxygenated blood. This is in line with our recently published results
involving metabolites measured in bronchoalveolar fluid before and after CPB, where we also found
no significant differences in the lactate levels among patients [44].
Previous work has shown that reduced oxygen concentrations during ischemia enhance
polyamine metabolism [61]. When compared with preoperative concentrations, the polyamine
metabolite arginine and its precursors—citrulline and proline—were increased in all three groups,
indicating increased oxidative stress. In line with these findings, we have recently demonstrated
an excess production of polyamine metabolites in the lungs of these patients at the end of CPB
(>40-fold) [44], indicating that reduced oxygenation during CPB not only affects the lungs, but also
has a systemic effect.
The TCA cycle intermediate 2-ketoglutarate is known to be consumed rapidly during ischemia,
since it both serves in ATP production [36] and detoxification of the increased amount of reactive
oxygen species (ROS) produced [62]. We observed a steep drop in its levels immediately after weaning
from CPB in the oxygenated blood and standard regimen groups, while its levels increased in the HTK
receiving patients. This increase can be explained by the addition of 2-ketoglutarate through the HTK
solution, and by a possible diffusion across the lungs into the systemic circuit. In the bronchoalveolar
fluid we found no change in the levels of 2-ketoglutarate and its precursor, succinate, at the end
of CPB in the HTK receiving patients, while their levels increased significantly in the oxygenated
blood and standard regimen patients [44]. This indicates that the body may have a mechanism to
mobilize the necessary substrates from the system to the organs experiencing severe energy depletion,
and vice versa. In the hours following CPB, the levels of 2-ketoglutarate dropped in the HTK group as
well; however, it never reached levels similar to the oxygenated blood and standard regimen groups.
The TCA cycle metabolite citrate was found to be elevated immediately after CPB in all patients,
with lower increases in the HTK group, indicating that 2-ketoglutarate provided some of the required
energy and protection against ROS formation. It is well known that ischemia-reperfusion injury and
the contact of blood with the extracorporeal CPB circuit activates the systemic inflammatory response,
which in turn generate excessive ROS [52]. Hence, it can be speculated that an increased concentration
of 2-ketoglutarate in the HTK solution could further minimize the production of citrate during CPB,
which in turn would ameliorate the production of ROS.
Changes in metabolites involved in nitrogen elimination via nitrogen metabolism and the urea
cycle were characteristic for patients receiving pulmonary artery perfusion with HTK solution during
CPB. Histidine and the metabolites involved in histidine catabolism (creatine, alanine, glycine,
glutamine, glutamate, threonine, and aspartate) were found to be significantly higher up to and
including the last measurement, at 20 h post-CPB. Histidine rose from its physiological pre-CPB
value of 0.068 mM to 6.4 mM at the end of CPB, due to HTK solution spillover from the pulmonary
to the systemic circuit, and reperfusion of the pulmonary circuit after cross-clamp release during
reestablishment of the patients own circulation. The byproduct of histidine and histidine-related
metabolites is urea. Plasma urea increased in all patients post-CPB and the HTK receiving patients
experienced elevated production four hours post-CPB. These findings are in line with previous
studies performed on plasma and urine from patients receiving cardioplegia with Bretschneider
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solution [42,43], which demonstrated high levels of urea and histidine in both plasma and urine until
72 h post-CPB. Previous work conducted on histidine administration to cardiac surgical patients
indicates a potential benefit of the intraoperative provision of the amino acids arising from its multiple
conversion pathways. For example, histidine administration mitigates the energy consuming systemic
inflammatory response, which develops postoperatively in all patients undergoing cardiac surgery
with CPB; and it also spares endogenous protein sources, like skeletal muscle, from degradation [42,43].
The potential benefit of amino acid administration is also described by Umenai et al. [63] who showed
positive effects of perioperative amino acid infusion in patients undergoing off-pump CABG, resulting
in significantly shorter durations of postoperative mechanical ventilation and time in the intensive care
unit. Lastly, we have previously demonstrated that histidine administration during CPB may have a
lung protective effect against severe acidosis, excessive fatty acid oxidation, and inflammation [44].
These results were performed on bronchoalveolar fluid and the next step will be to investigate how
HTK solution affects the composition of lung tissue.
4.3. Strengths and Limitations
Metabonomics represents an advance over other system-wide approaches, yet several limitations
are relevant to the interpretation of our study. Firstly, hypoxemia and acute respiratory
distress syndrome are common postoperative pulmonary dysfunctions following cardiac surgery,
which develop 48–72 h after the end of surgery, with gradual improvement within several days [2,64].
Due to the limited follow-up of our study (20 h post-CPB), we could not assess whether the use of
pulmonary artery perfusion regimens could have prevented the development of these postoperative
complications. Clinical and metabolite outcomes were not measured at the time of maximal damage,
which impairs the generalizability of our observations. These observations should therefore be
interpreted as the first steps towards a more detailed description of pulmonary injury on the second
to third postoperative days. Secondly, conducting clinical trials with a cohort of complex critically ill
patients, where outcomes will be determined primarily by the severity of their underlying illness, is
challenging. Although cardiac surgical patients are a relatively homogeneous group, the inevitable
heterogeneity may leave this sub-study underpowered to detect group differences in relation to clinical
outcomes and metabolite estimates, and specifically, for the comparison of pulmonary artery perfusion
with oxygenated blood to standard CPB.
5. Conclusions
In this descriptive sub-study of the Pulmonary Protection Trial we found that arterial blood gas
analyses, IL-6, and several metabolites changed significantly in the peri- and postoperative period
in cardiac surgery patients with COPD. When comparing the molecular and electrolyte differences
between pulmonary artery perfusion with oxygenated blood to the standard regimen, similar patterns
were observed during and after CPB. These observations indicate that the additional blood supply
does not, as hypothesized, alter what is already achieved by the bronchial arteries. When comparing
the differences between pulmonary artery perfusion with HTK solution to oxygenated blood or the
standard regimen, we found that some of the HTK solution enters the systemic circuit and elicits
a significant impact on arterial blood gas analyses and metabolites, with some of the effects still
present 20 h after its administration. Results confirm the development of an isotonic hyponatremia
following administration of HTK solution, and that this should not be corrected without concomitant
hypotonicity. In addition, although plasma IL-6 levels increased in all patients during and after
CPB, HTK receiving patients had, in general, lower levels of this inflammatory protein; however, the
difference was not statistically significant. Metabolite data indicate that pulmonary perfusion with HTK
during CPB may provide some of the necessary substrates needed to counteract ischemia-reperfusion
injury, protect against severe energy depletion, and ameliorate ROS production. Additional studies are
needed to confirm the metabolite results and further elucidate how to diminish ischemia-reperfusion
injury of the lungs during CPB to reduce the risk of developing acute respiratory distress syndrome.
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